NCT03755141View on ClinicalTrials.gov

Efficacy and Safety of Trastuzumab Biosimilar (Herzuma®) Plus Treatment of Physician's Choice (TPC) in Patients With HER-2 Positive Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

109

Participants

Timeline

Start Date

December 15, 2018

Primary Completion Date

August 24, 2021

Study Completion Date

June 30, 2022

Conditions

HER2-positive Breast CancerMetastatic Breast Cancer

Interventions

DRUG

Herzuma

Herzuma + Treatment of Physician's Choice

Trial Locations (1)

08308

Korea University, Guro hospital, Seoul

All Listed Sponsors

lead

National Cancer Center, Korea

OTHER_GOV

NCT03755141 - Efficacy and Safety of Trastuzumab Biosimilar (Herzuma®) Plus Treatment of Physician's Choice (TPC) in Patients With HER-2 Positive Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter